Conference abstract · 25 Aug 2015
Conference abstractPublished 25 Aug 2015
Lessons learned from randomized clinical trials of oral immunosuppressive therapies in reduction of restenosis after bare metal stent implantation: Are enough evidence for class ii-a indication?
Otamendi Hospital, Argentina
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Coronary restenosis after Percutaneous Coronary Interventions (PCI) has been significantly reduced in the last decade after the introduction of Drug Eluting Stents (DES), clinically reproduced by a significant decrease of repeat revascularization procedures. However, in certain group of patients, this benefit did not translate to better clinical outcomes in the long run compared to previous Bare Metal Stents (BMS) implantation. Hard clinical endpoints, such as death, myocardial infarction or cerebrovascular accidents did not diminish as was expected, especially in the subgroup who couldn´t receive dual antiplatelet therapy for long time. While newer generations of DES and antiplatelet drugs developed, registries and Randomized Clinical Trials (RCT) with Oral Immunosuppressive Therapies (OIT) to prevent restenosis after BMS implantation demonstrated a significant improvement reducing restenosis and target vessel revascularization without increasing hard clinical end-points or serious adverse side effects. However, these investigator´s driven studies had limitations, mainly due to small sample size. Last year a meta-analysis of OIT, either with sirolimus or prednisone, was published and results were in accordance with previous data. At the same time an important RCT, Oral treatment with Rapamycin in Argentina (ORAR III), published 5 years follow-up data comparing 1st generation DES and showed promising results in favor of OIT. Actually, this strategy of OIT after BMS appears to be rational when patients had restrictions or contraindications for DES or if there are economic limitations in the health care system, and therefore it would be appropriate to include this approach as a Class IIA indication..
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Research article · 2015
Cilostazol Added to Dual Antiplatelet Therapy for Patients with High Risk of Restenosis after Drug-Eluting Stent Implantation: A Systematic Review and Meta-Analysis of RCTs
Conference abstract · 29 Nov 2015
Treatment of bare metal stent in-stent restenosis with balloon angioplasty alone versus stenting: meta-analysis of randomized controlled trial
Research article · 28 Dec 2023
The Prognosis of Optical Coherence Tomography-Guided Versus Intravascular Ultrasound-Guided Implantation of Drug-Eluting Stents: A Meta-Analysis from Randomized Controlled Trials
Editorial · Sep 2019
Contribution of Surgical Procedures Including Insertions of Implants, Stents, and Pacemakers to Longevity Prospective Controlled Randomized Study of Large-Balloon-Dilatation Versus Mechanical Lithotripsy for Large Bile Duct Stone
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectDentistry & Oral Health
- SubjectImmunology & Microbiology
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Alfredo E Rodriguez”
